Celularity
Florham Park · Founded 2017
About Celularity
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $410.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2025)
- Ticker: nasdaq:CELU
- Website: celularity.com
- Phone: 908-768-2170
Industries & Categories
Biotechnology, Health Care, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/celularity-102440 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.